{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:37:38Z","timestamp":1774042658955,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P50 MH086385"],"award-info":[{"award-number":["P50 MH086385"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11064-016-1838-8","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T14:28:32Z","timestamp":1454941712000},"page":"398-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Modulating NMDA Receptor Function with d-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model"],"prefix":"10.1007","volume":"41","author":[{"given":"Henry","family":"Sershen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Suckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom B.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Javitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,8]]},"reference":[{"key":"1838_CR1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/schbul\/sbs100","volume":"38","author":"DC Javitt","year":"2012","unstructured":"Javitt DC (2012) Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr Bull 38:911\u2013913","journal-title":"Schizophr Bull"},{"key":"1838_CR2","doi-asserted-by":"publisher","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","volume":"93","author":"M Laruelle","year":"1996","unstructured":"Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D\u2019Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235\u20139240","journal-title":"Proc Natl Acad Sci USA"},{"key":"1838_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0006-3223(00)00976-8","volume":"48","author":"LS Kegeles","year":"2000","unstructured":"Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627\u2013640","journal-title":"Biol Psychiatry"},{"key":"1838_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/2045125314557797","volume":"5","author":"H Steeds","year":"2015","unstructured":"Steeds H, Carhart-Harris RL, Stone JM (2015) Drug models of schizophrenia. Ther Adv Psychopharmacol 5:43\u201358","journal-title":"Ther Adv Psychopharmacol"},{"key":"1838_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv151","author":"E Mouchlianitis","year":"2015","unstructured":"Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, Waldman A, Turkheimer FE, Egerton A, Stone J, Howes OD (2015) Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. doi: 10.1093\/schbul\/sbv151","journal-title":"Schizophr Bull"},{"key":"1838_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH (2015) Antipsychotic medication in schizophrenia: a review. Br Med Bull 114:169\u2013179","journal-title":"Br Med Bull"},{"key":"1838_CR7","first-page":"731","volume":"32","author":"U Heresco-Levy","year":"1996","unstructured":"Heresco-Levy U, Silipo G, Javitt DC (1996) Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 32:731\u2013740","journal-title":"Psychopharmacol Bull"},{"key":"1838_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.euroneuro.2012.09.008","volume":"23","author":"SW Woods","year":"2013","unstructured":"Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D\u2019Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH (2013) Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol 23:931\u2013940","journal-title":"Eur Neuropsychopharmacol"},{"key":"1838_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D\u2019Souza C, Saksa J, Woods SW, Javitt DC (2010) High dose d-serine in the treatment of schizophrenia. Schizophr Res 121:125\u2013130","journal-title":"Schizophr Res"},{"key":"1838_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S2215-0366(15)00098-X","volume":"2","author":"JT Kantrowitz","year":"2015","unstructured":"Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, Silipo G, Javitt DC (2015) d-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2:403\u2013412","journal-title":"Lancet Psychiatry"},{"key":"1838_CR11","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.4088\/JCP.11m07031","volume":"73","author":"M Weiser","year":"2012","unstructured":"Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y (2012) A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 73:e728\u2013e734","journal-title":"J Clin Psychiatry"},{"key":"1838_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","volume":"265","author":"HJ Moller","year":"2015","unstructured":"Moller HJ, Czobor P (2015) Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 265:567\u2013578","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1838_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tox.2004.05.001","volume":"201","author":"RE Williams","year":"2004","unstructured":"Williams RE, Lock EA (2004) d-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism. Toxicology 201:231\u2013238","journal-title":"Toxicology"},{"key":"1838_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40501-014-0010-9","volume":"1","author":"DC Javitt","year":"2015","unstructured":"Javitt DC (2015) Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia. Curr Treat Options Psychiatry 1:107\u2013120","journal-title":"Curr Treat Options Psychiatry"},{"key":"1838_CR15","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1523\/JNEUROSCI.17-12-04580.1997","volume":"17","author":"S Supplisson","year":"1997","unstructured":"Supplisson S, Bergman C (1997) Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 17:4580\u20134590","journal-title":"J Neurosci"},{"key":"1838_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.npp.1300589","volume":"30","author":"DC Javitt","year":"2005","unstructured":"Javitt DC, Hashim A, Sershen H (2005) Modulation of striatal dopamine release by glycine transport inhibitors. Neuropsychopharmacology 30:649\u2013656","journal-title":"Neuropsychopharmacology"},{"key":"1838_CR17","first-page":"12","volume":"52","author":"R Amiaz","year":"2015","unstructured":"Amiaz R, Kent I, Rubinstein K, Sela BA, Javitt D, Weiser M (2015) Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia\u2014preliminary study. Isr J Psychiatry Relat Sci 52:12\u201315","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"1838_CR18","doi-asserted-by":"publisher","first-page":"8767","DOI":"10.3390\/nu7105427","volume":"7","author":"D Strzelecki","year":"2015","unstructured":"Strzelecki D, Podgorski M, Kaluzynska O, Gawlik-Kotelnicka O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P (2015) Supplementation of antipsychotic treatment with the amino acid sarcosine influences proton magnetic resonance spectroscopy parameters in left frontal white matter in patients with schizophrenia. Nutrients 7:8767\u20138782","journal-title":"Nutrients"},{"key":"1838_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15622975.2015.1117654","volume":"22","author":"CY Lin","year":"2015","unstructured":"Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY (2015) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry 22:1\u201312","journal-title":"World J Biol Psychiatry"},{"key":"1838_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.brainres.2006.05.082","volume":"1106","author":"R Kapoor","year":"2006","unstructured":"Kapoor R, Lim KS, Cheng A, Garrick T, Kapoor V (2006) Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res 1106:205\u2013210","journal-title":"Brain Res"},{"key":"1838_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.schres.2008.02.002","volume":"101","author":"C Madeira","year":"2008","unstructured":"Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R (2008) Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 101:76\u201383","journal-title":"Schizophr Res"},{"key":"1838_CR22","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.biopsych.2009.01.002","volume":"65","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, Tsukamoto T (2009) Co-administration of a d-amino acid oxidase inhibitor potentiates the efficacy of d-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 65:1103\u20131106","journal-title":"Biol Psychiatry"},{"key":"1838_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/neu.2015.1","volume":"27","author":"A Matsuura","year":"2015","unstructured":"Matsuura A, Fujita Y, Iyo M, Hashimoto K (2015) Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatry 27:159\u2013167","journal-title":"Acta Neuropsychiatry"},{"key":"1838_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","volume":"70","author":"HY Lane","year":"2013","unstructured":"Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE (2013) Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor. JAMA Psychiatry 70:1267\u20131275","journal-title":"JAMA Psychiatry"},{"key":"1838_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","volume":"19","author":"KQ Do","year":"2009","unstructured":"Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19:220\u2013230","journal-title":"Curr Opin Neurobiol"},{"key":"1838_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0378-4347(92)80300-F","volume":"582","author":"A Hashimoto","year":"1992","unstructured":"Hashimoto A, Nishikawa T, Oka T, Takahashi K, Hayashi T (1992) Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-l-cysteine and o-phthaldialdehyde. J Chromatogr 582:41\u201348","journal-title":"J Chromatogr"},{"key":"1838_CR27","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1023\/A:1021607715824","volume":"27","author":"A Neidle","year":"2002","unstructured":"Neidle A, Dunlop DS (2002) Allosteric regulation of mouse brain serine racemase. Neurochem Res 27:1719\u20131724","journal-title":"Neurochem Res"},{"key":"1838_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0361-9230(00)00258-6","volume":"52","author":"DC Javitt","year":"2000","unstructured":"Javitt DC, Sershen H, Hashim A, Lajtha A (2000) Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res Bull 52:213\u2013216","journal-title":"Brain Res Bull"},{"key":"1838_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.phanu.2012.10.004","volume":"1","author":"RK McNamara","year":"2013","unstructured":"McNamara RK, Strawn JR (2013) Role of long-chain omega-3 fatty acids in psychiatric practice. PharmaNutrition 1:41\u201349","journal-title":"PharmaNutrition"},{"key":"1838_CR30","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.pnpbp.2007.07.004","volume":"31","author":"EY Sivrioglu","year":"2007","unstructured":"Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandol E (2007) The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31:1493\u20131499","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1838_CR31","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1038\/tp.2013.110","volume":"3","author":"H Bentsen","year":"2013","unstructured":"Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T (2013) A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E\u00a0+\u00a0C in schizophrenia. Transl Psychiatry 3:e335","journal-title":"Transl Psychiatry"},{"key":"1838_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0893-133X(97)00047-X","volume":"17","author":"DC Javitt","year":"1997","unstructured":"Javitt DC, Sershen H, Hashim A, Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202\u2013204","journal-title":"Neuropsychopharmacology"},{"key":"1838_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.npp.1300313","volume":"29","author":"DC Javitt","year":"2004","unstructured":"Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H (2004) Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor\/glycine-site agonists. Neuropsychopharmacology 29:300\u2013307","journal-title":"Neuropsychopharmacology"},{"key":"1838_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.npp.1300589","volume":"30","author":"DC Javitt","year":"2005","unstructured":"Javitt DC, Hashim A, Sershen H (2005) Modulation of striatal dopamine release by glycine transport inhibitors. Neuropsychopharmacology 30:649\u2013656","journal-title":"Neuropsychopharmacology"},{"key":"1838_CR35","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.euroneuro.2012.03.006","volume":"22","author":"A Balla","year":"2012","unstructured":"Balla A, Schneider S, Sershen H, Javitt DC (2012) Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia. Eur Neuropsychopharmacol 22:902\u2013910","journal-title":"Eur Neuropsychopharmacol"},{"key":"1838_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4684-5769-8_3","volume":"268","author":"R Dingledine","year":"1990","unstructured":"Dingledine R, Kleckner NW, McBain CJ (1990) The glycine coagonist site of the NMDA receptor. Adv Exp Med Biol 268:17\u201326","journal-title":"Adv Exp Med Biol"},{"key":"1838_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1054-3589(08)60340-3","volume":"21","author":"IJ Reynolds","year":"1990","unstructured":"Reynolds IJ, Miller RJ (1990) Allosteric modulation of N-methyl-d-aspartate receptors. Adv Pharmacol 21:101\u2013126","journal-title":"Adv Pharmacol"},{"key":"1838_CR38","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0028-3908(88)90015-9","volume":"27","author":"E Fadda","year":"1988","unstructured":"Fadda E, Danysz W, Wroblewski JT, Costa E (1988) Glycine and d-serine increase the affinity of N-methyl-d-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. Neuropharmacology 27:1183\u20131185","journal-title":"Neuropharmacology"},{"key":"1838_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","volume":"213","author":"DC Javitt","year":"2012","unstructured":"Javitt DC (2012) Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 213:367\u2013399","journal-title":"Handb Exp Pharmacol"},{"key":"1838_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0091-3057(02)01078-X","volume":"74","author":"LG Harsing Jr","year":"2003","unstructured":"Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811\u2013825","journal-title":"Pharmacol Biochem Behav"},{"key":"1838_CR41","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2174\/1381612821666150109125623","volume":"21","author":"LG Harsing Jr","year":"2015","unstructured":"Harsing LG Jr, Timar J, Szabo G, Udvari S, Nagy KM, Marko B, Zsilla G, Czompa A, Tapolcsanyi P, Kocsis A, Matyus P (2015) Sarcosine-based glycine transporter type-1 (GlyT-1) inhibitors containing pyridazine moiety: a further search for drugs with potential to influence schizophrenia negative symptoms. Curr Pharm Des 21:2291\u20132303","journal-title":"Curr Pharm Des"},{"key":"1838_CR42","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71:637\u2013646","journal-title":"JAMA Psychiatry"},{"key":"1838_CR43","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.2174\/1381612821666150724100952","volume":"21","author":"P Singer","year":"2015","unstructured":"Singer P, Dubroqua S, Yee BK (2015) Inhibition of glycine transporter 1: the yellow brick road to new schizophrenia therapy? Curr Pharm Des 21:3771\u20133787","journal-title":"Curr Pharm Des"},{"key":"1838_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1124\/jpet.108.147884","volume":"328","author":"SM Smith","year":"2009","unstructured":"Smith SM, Uslaner JM, Yao L, Mullins CM, Surles NO, Huszar SL, McNaughton CH, Pascarella DM, Kandebo M, Hinchliffe RM, Sparey T, Brandon NJ, Jones B, Venkatraman S, Young MB, Sachs N, Jacobson MA, Hutson PH (2009) The behavioral and neurochemical effects of a novel d-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and d-serine. J Pharmacol Exp Ther 328:921\u2013930","journal-title":"J Pharmacol Exp Ther"},{"key":"1838_CR45","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.neuropharm.2011.06.029","volume":"61","author":"CA Strick","year":"2011","unstructured":"Strick CA, Li C, Scott L, Harvey B, Hajos M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD III, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ (2011) Modulation of NMDA receptor function by inhibition of d-amino acid oxidase in rodent brain. Neuropharmacology 61:1001\u20131015","journal-title":"Neuropharmacology"},{"key":"1838_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.319","author":"C Rojas","year":"2015","unstructured":"Rojas C, Alt J, Ator NA, Thomas AG, Wu Y, Hin N, Wozniak K, Ferraris D, Rais R, Tsukamoto T, Slusher BS (2015) d-Amino-acid oxidase inhibition increases d-serine plasma levels in mouse but not in monkey or dog. Neuropsychopharmacology. doi: 10.1038\/npp.2015.319","journal-title":"Neuropsychopharmacology"},{"key":"1838_CR47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.euroneuro.2007.06.006","volume":"18","author":"T Adage","year":"2008","unstructured":"Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, Guerassimenko O, Giachetti C, Greco B, Chumakov I, Halazy S, Roach A, Zaratin P (2008) In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 18:200\u2013214","journal-title":"Eur Neuropsychopharmacol"},{"key":"1838_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.arcmed.2014.11.020","volume":"45","author":"M Vecsernyes","year":"2014","unstructured":"Vecsernyes M, Fenyvesi F, Bacskay I, Deli MA, Szente L, Fenyvesi E (2014) Cyclodextrins, blood\u2013brain barrier, and treatment of neurological diseases. Arch Med Res 45:711\u2013729","journal-title":"Arch Med Res"},{"key":"1838_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/neu.2015.1","volume":"27","author":"A Matsuura","year":"2015","unstructured":"Matsuura A, Fujita Y, Iyo M, Hashimoto K (2015) Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatry 27:159\u2013167","journal-title":"Acta Neuropsychiatry"},{"key":"1838_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/0885-4505(91)90050-U","volume":"46","author":"AG Palekar","year":"1991","unstructured":"Palekar AG, Kalbag SS (1991) Amino acids in the rat liver and plasma and some metabolites in the liver after sodium benzoate treatment. Biochem Med Metab Biol 46:52\u201358","journal-title":"Biochem Med Metab Biol"},{"key":"1838_CR51","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1172\/JCI102014","volume":"27","author":"A de Vries","year":"1948","unstructured":"de Vries A, Alexander B, Quamo Y (1948) Studies on amino acid metabolism. III. Plasma glycine concentration and hippuric acid formation following the ingestion of benzoate. J Clin Invest 27:665\u2013668","journal-title":"J Clin Invest"},{"key":"1838_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgme.2014.11.010","volume":"114","author":"BS Lennerz","year":"2015","unstructured":"Lennerz BS, Vafai SB, Delaney NF, Clish CB, Deik AA, Pierce KA, Ludwig DS, Mootha VK (2015) Effects of sodium benzoate, a widely used food preservative, on glucose homeostasis and metabolic profiles in humans. Mol Genet Metab 114:73\u201379","journal-title":"Mol Genet Metab"},{"key":"1838_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.mp.4001552","volume":"10","author":"DC Javitt","year":"2005","unstructured":"Javitt DC, Duncan L, Balla A, Sershen H (2005) Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10:275\u2013287","journal-title":"Mol Psychiatry"},{"key":"1838_CR54","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1176\/appi.ajp.162.9.1738","volume":"162","author":"G Neeman","year":"2005","unstructured":"Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162:1738\u20131740","journal-title":"Am J Psychiatry"},{"key":"1838_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145703003900","volume":"7","author":"T Sumiyoshi","year":"2004","unstructured":"Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7:1\u20138","journal-title":"Int J Neuropsychopharmacol"},{"key":"1838_CR56","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1017\/S1461145705005237","volume":"8","author":"T Sumiyoshi","year":"2005","unstructured":"Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY (2005) Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol 8:451\u2013455","journal-title":"Int J Neuropsychopharmacol"},{"key":"1838_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2005.10.015","volume":"527","author":"S Bennett","year":"2005","unstructured":"Bennett S, Gronier B (2005) Modulation of striatal dopamine release in vitro by agonists of the glycine B site of NMDA receptors; interaction with antipsychotics. Eur J Pharmacol 527:52\u201359","journal-title":"Eur J Pharmacol"},{"key":"1838_CR58","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.neuropharm.2009.01.021","volume":"56","author":"A Balla","year":"2009","unstructured":"Balla A, Nattini ME, Sershen H, Lajtha A, Dunlop DS, Javitt DC (2009) GABAB\/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum. Neuropharmacology 56:915\u2013921","journal-title":"Neuropharmacology"},{"key":"1838_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12888-015-0473-2","volume":"15","author":"T Pawelczyk","year":"2015","unstructured":"Pawelczyk T, Grancow M, Kotlicka-Antczak M, Trafalska E, Gebski P, Szemraj J, Zurner N, Pawelczyk A (2015) Omega-3 fatty acids in first-episode schizophrenia\u2014a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. BMC Psychiatry 15:97","journal-title":"BMC Psychiatry"},{"key":"1838_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1113\/jphysiol.1994.sp020051","volume":"475","author":"M Nishikawa","year":"1994","unstructured":"Nishikawa M, Kimura S, Akaike N (1994) Facilitatory effect of docosahexaenoic acid on N-methyl-d-aspartate response in pyramidal neurones of rat cerebral cortex. J Physiol 475:83\u201393","journal-title":"J Physiol"},{"key":"1838_CR61","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jnr.490170315","volume":"17","author":"H Sershen","year":"1987","unstructured":"Sershen H, Debler EA, Lajtha A (1987) Effect of ascorbic acid on the synaptosomal uptake of [3H]MPP+, [3H]dopamine, and [14C]GABA. J Neurosci Res 17:298\u2013301","journal-title":"J Neurosci Res"},{"key":"1838_CR62","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/0024-3205(88)90323-2","volume":"42","author":"EA Debler","year":"1988","unstructured":"Debler EA, Hashim A, Lajtha A, Sershen H (1988) Ascorbic acid and striatal transport of [3H] 1-methyl-4-phenylpyridine (MPP+) and [3H] dopamine. Life Sci 42:2553\u20132559","journal-title":"Life Sci"},{"key":"1838_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/syn.890070203","volume":"7","author":"EA Debler","year":"1991","unstructured":"Debler EA, Sershen H, Hashim A, Lajtha A, Reith ME (1991) Carrier-mediated efflux of [3H]dopamine and [3H]1-methyl-4-phenylpyridine: effect of ascorbic acid. Synapse 7:99\u2013105","journal-title":"Synapse"},{"key":"1838_CR64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2202-8-32","volume":"8","author":"MI Sandstrom","year":"2007","unstructured":"Sandstrom MI, Rebec GV (2007) Extracellular ascorbate modulates glutamate dynamics: role of behavioral activation. BMC Neurosci 8:32","journal-title":"BMC Neurosci"},{"key":"1838_CR65","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/0006-8993(90)90379-P","volume":"537","author":"MD Majewska","year":"1990","unstructured":"Majewska MD, Bell JA, London ED (1990) Regulation of the NMDA receptor by redox phenomena: inhibitory role of ascorbate. Brain Res 537:328\u2013332","journal-title":"Brain Res"},{"key":"1838_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/0301-0082(94)90052-3","volume":"43","author":"GV Rebec","year":"1994","unstructured":"Rebec GV, Pierce RC (1994) A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog Neurobiol 43:537\u2013565","journal-title":"Prog Neurobiol"},{"key":"1838_CR67","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0022-3565(25)22395-3","volume":"270","author":"DC Javitt","year":"1994","unstructured":"Javitt DC, Frusciante MJ, Zukin SR (1994) Activation-related and activation-independent effects of polyamines on phencyclidine receptor binding within the N-methyl-d-aspartate receptor complex. J Pharmacol Exp Ther 270:604\u2013613","journal-title":"J Pharmacol Exp Ther"},{"key":"1838_CR68","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1073\/pnas.86.2.740","volume":"86","author":"DC Javitt","year":"1989","unstructured":"Javitt DC, Zukin SR (1989) Interaction of [3H]MK-801 with multiple states of the N-methyl-d-aspartate receptor complex of rat brain. Proc Natl Acad Sci USA 86:740\u2013744","journal-title":"Proc Natl Acad Sci USA"},{"key":"1838_CR69","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2174\/157015911795596504","volume":"9","author":"I Bokkon","year":"2011","unstructured":"Bokkon I, Antal I (2011) Schizophrenia: redox regulation and volume neurotransmission. Curr Neuropharmacol 9:289\u2013300","journal-title":"Curr Neuropharmacol"},{"key":"1838_CR70","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2012.06.029","volume":"150","author":"T Papouin","year":"2012","unstructured":"Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet JP, Oliet SH (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150:633\u2013646","journal-title":"Cell"},{"key":"1838_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1874104501004020003","volume":"4","author":"SM Smith","year":"2010","unstructured":"Smith SM, Uslaner JM, Hutson PH (2010) The therapeutic potential of d-amino acid oxidase (DAAO) inhibitors. Open Med Chem J 4:3\u20139","journal-title":"Open Med Chem J"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-016-1838-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1838-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:58:34Z","timestamp":1748771914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-016-1838-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":71,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1007\/s11064-016-1838-8","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"7 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}